Rituximab-vemurafenib combination for the treatment of relapsed/Refractory hairy cell leukemia

Abstract

Objective: The management of R/R-HCL is not standardized yet. Patients with HCL universally harbor BRAF mutations, which makes BRAF inhibitors a potential treatment approach. The effi cacy and safety of the BRAF inhibitor Vemurafenib were evaluated both as a single-agent option in two phase 2 trials and also combined with Rituximab in another phase 2 trial. Patients: We have decided to present the fi rst two consecutive patients who achieved a rapid and prolonged response, relapsing after treatment with purine analogues. The fi rst two patients who received a combination of R-V for R/R HCL from the records of our institutional CLPD registry were reported.